We performed a screening of miRNAs regulated by dietary lipids in a cellular model of enterocytes, Caco-2 cells. Our aim was to describe new lipid-modified miRNAs with an implication in lipid homeostasis and cardiovascular disease [1, 2] . For that purpose, we treated differentiated Caco-2 cells with micelles containing the assayed lipids (cholesterol, conjugated linoleic acid and docosahexaenoic acid) and the screening of miRNAs was carried out by microarray using the μParaflo®Microfluidic Biochip Technology of LC Sciences (Huston, TX, USA). Experimental design, microarray description and raw data have been made available in the GEO database with the reference number of GSE59153. Here we described in detail the experimental design and methods used to obtain the relative expression data.
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Experimental design, materials and methods
For differentiation, Caco-2 cells were plated on polycarbonate Transwell® filter inserts of 0.4 μm pore size (Costar, Madrid, Spain) in 6-well plates. Approximately 14 days after confluence cells develop morphologic and physiologic characteristics of normal enterocytes [3] . Cholesterol (Chol), CLA and DHA (Sigma, Madrid, Spain) were delivered to cells as micelles with Lyso-phosphatidylcholine (Lyso-PC; Sigma, Madrid, Spain) and sodium taurocholate (Tau; Sigma, Madrid, Spain) [4] . Briefly, Chol (250 μM), CLA (200 μM) or DHA (200 μM) were diluted in n-hexane (Scharlab; Barcelona, Spain) and dried under a nitrogen stream. Lyso-PC (200 μM) was also diluted in n-hexane and mixed with the dried Chol, CLA or DHA, respectively. The mixture was then dried under a nitrogen stream. Tau (5 mM) was diluted in ethanol 95% and added to the Lyso-PC/lipid mixture and then evaporated under a nitrogen stream. The resulted micelles were diluted in a serum-free medium and mixed vigorously until clear. As control, we used empty micelles made with Lyso-PC and Tau. Four control and cholesterol samples, three DHA samples and two CLA samples were analyzed.
MicroRNA-enriched total RNA was isolated with miRNeasy mini kit (Qiagen, Madrid, Spain) following manufacturer's instructions. Total RNA concentration was quantified with a Nanodrop and the integrity was confirmed in a 1% agarose gel.
The expression of microRNAs contained in the miRBase version 17 was analyzed by microarray using the μParaflo®Microfluidic Biochip Technology of LCsciences (Huston, TX, USA). A total of 1 μg of miRNAenriched RNA was used for miRNA microarray. At least three samples of each condition were analyzed (except for CLA, for which we processed
